Evidence map›Paper›PMID 30348535›Full record

SynthesisAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2019

Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium.

Lesley A Inker, Morgan E Grams, Andrew S Levey, Josef Coresh, Massimo Cirillo, John F Collins, Ron T Gansevoort, Orlando M Gutierrez, Takayuki Hamano, Gunnar H Heine and 18 more

Registry-linked trialOpen access · bronzeAbstract readMeta-AnalysisMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07494266 (Säkerheten av en hälsosam växtbaserad Kost Med högre kaliuminnerhåll, jämfört Med en hälsosam växtbaserad Kost Med begränsat kaliuminnehåll Hos Patienter Med Kronisk Njursjukdom), which is not on this map. Cited by 49 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 4 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07494266 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Säkerheten av en hälsosam växtbaserad Kost Med högre kaliuminnerhåll, jämfört Med en hälsosam växtbaserad Kost Med begränsat kaliuminnehåll Hos Patienter Med Kronisk Njursjukdom: En Pilotstudie

TypeinterventionalSponsorKarolinska InstitutetRan2026 to 2030Enrolled30ConditionsHyperkalemia, Chronic Kidney Disease (Stages 4 and 5)ArmsHealthy plant-based diet (healthy-PBD), Potassium-restricted plant-based diet
3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 4 syntheses or guidelines pooled it, 92 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Framework of Guidelines for Management of CKD in Asia.Kidney international reports · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 20 institutions in 13 countries.

Lesley A InkerDivision of Nephrology, Tufts Medical Center, Boston, MA.
Morgan E GramsJohns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Andrew S LeveyDivision of Nephrology, Tufts Medical Center, Boston, MA.
Josef CoreshJohns Hopkins Bloomberg School of Public Health, Baltimore, MD. Electronic address: ckdpc@jhmi.edu.
Massimo CirilloDepartment "Scuola Medica Salernitana", University of Salerno, Italy.
John F CollinsDepartment of Renal Medicine, Auckland City Hospital, Auckland, New Zealand.
Ron T GansevoortDepartment of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Orlando M GutierrezDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL; Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL.
Takayuki HamanoDepartment of Comprehensive Kidney Disease Research, Osaka University Graduate School of Medicine, Osaka, Japan.
Gunnar H HeineDepartment for Internal Medicine IV, Nephrology and Hypertension, Saarland University Medical Center, Homburg, Germany.
Shizukiyo IshikawaDivision of Community and Family Medicine, Center for Community Medicine, Jichi Medical University, Tochigi, Japan.
Sun Ha JeeDepartment of Epidemiology and Health Promotion, Graduate School of Public Health, Yonsei University, Seoul, Korea.
Florian KronenbergDivision of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria and German Chronic Kidney Disease Study, Oxford, United Kingdom.
Martin J LandrayMedical Research Council-Population Health Research Unit, Clinical Trial Service Unit and Epidemiological Studies Unit, and Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Katsuyuki MiuraDepartment of Public Health and Center for Epidemiologic Research in Asia, Shiga University of Medical Science, Otsu, Japan.
Girish N NadkarniDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Carmen A PeraltaKidney Health Research Collaborative, San Francisco VA Medical Center and University of California, San Francisco, CA.
Dietrich RothenbacherDivision of Clinical Epidemiology and Ageing Research, German Cancer Centre (DKFZ), Heidelberg; Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
Elke SchaeffnerInstitute of Public Health, Charite, Universitätsmedizin Berlin.
Sanaz SedaghatDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Michael G ShlipakKidney Health Research Collaborative, San Francisco VA Medical Center and University of California, San Francisco, CA.
Luxia ZhangPeking University Institute of Nephrology, Division of Nephrology, Peking University First Hospital, Beijing, China.
Arjan D van ZuilenDepartment of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, the Netherlands.
Stein I HallanDepartment of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science Technology, Trondheim, Norway; Division of Nephrology, Department of Medicine, St Olav University Hospital, Trondheim, Norway.
Csaba P KovesdyMemphis Veterans Affairs Medical Center, Memphis, TN; University of Tennessee Health Science Center, Memphis, TN.
Mark WoodwardJohns Hopkins Bloomberg School of Public Health, Baltimore, MD; The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; The George Institute for Global Health, University of Oxford, Oxford, United Kingdom.
Adeera LevinBC Provincial Renal Agency and University of British Columbia, Canada.
CKD Prognosis Consortium
Johns Hopkins University · USAuckland City Hospital · NZShiga University of Medical Science · JPTufts Medical Center · USUniversity of Oxford · GBPeking University First Hospital · CNSan Francisco VA Medical Center · USUniversity Medical Center Utrecht · NLBC Cancer Agency · CACharité - Universitätsmedizin Berlin · DEErasmus MC · NLIcahn School of Medicine at Mount Sinai · USInnsbruck Medical University · ATJichi Medical University · JPSaarland University · DESt Olav's University Hospital · NOThe University of Osaka · JPUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USUniversity of Groningen · NL

Funding

VCID and Stroke in a Bi-racial National CohortU01NS041588 · NINDS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CUSHMAN, MARY, HOWARD, GEORGE · 2002 to 2022
$96.0M
ZOVIRAX CREAM TO TREAT HERPES LABIALIS IN ADOLESCENTSM01RR000827 · NCRR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAAS, RICHARD H · 1985 to 2010
$74.3M
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
ZIPRASIDONE (GEODON) AUGMENTATION IN SEROTONIN REUPTAKE INHIBITOR-RESISTANT OBM01RR000071 · NCRR · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI GOODMAN, MARC T · 1985 to 2009
$41.5M
ZINC AND CA EDTA THERAPY OF PLUMBISMM01RR000052 · NCRR · JOHNS HOPKINS UNIVERSITY · PI MARSH, LAURA · 1985 to 2007
$37.3M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Zevalin Radioimmunotherapy Using a Modified TreatmentM01RR000032 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RICH, ROBERT R. · 1985 to 2008
$23.6M
Zosuquidar trihydrochloride for acute myeloid leukemia &refractory anemiaM01RR000080 · NCRR · UNIVERSITY HOSPITALS OF CLEVELAND · PI DEARBORN, DORR GELLATLY · 1985 to 2007
$22.2M
ZINC THERAPY FOR SCLERODERMA--PHASE I STUDYM01RR002719 · NCRR · JOHNS HOPKINS UNIVERSITY · PI SEO, PHILIP · 1986 to 2007
$20.2M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
YQ MICRODELETIONS AND MALE INFERTILITYP20RR011145 · NCRR · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI NORRIS, KEITH C · 1995 to 2009
$17.0M
WARCEFP20RR011104 · NCRR · MOREHOUSE SCHOOL OF MEDICINE · PI FUKUHARA, CHIAKI · 1995 to 2009
$14.5M
NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR001079NCRR NIH HHS M01 RR000032NCRR NIH HHS M01 RR000052NCRR NIH HHS M01 RR000071NCRR NIH HHS M01 RR000080NCRR NIH HHS M01 RR000827NCRR NIH HHS M01 RR002719NCRR NIH HHS P20 RR011104NCRR NIH HHS P20 RR011145NHLBI NIH HHS HHSN268200800007CNHLBI NIH HHS HHSN268201200036CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS HHSN268201700001INHLBI NIH HHS HHSN268201700002INHLBI NIH HHS HHSN268201700003INHLBI NIH HHS HHSN268201700004INHLBI NIH HHS HHSN268201700005INHLBI NIH HHS N01 HC025195NHLBI NIH HHS N01 HC055222NHLBI NIH HHS N01 HC085079NHLBI NIH HHS N01 HC085080NHLBI NIH HHS N01 HC085081NHLBI NIH HHS N01 HC085082NHLBI NIH HHS N01 HC085083NHLBI NIH HHS N01 HC085086NHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095166NHLBI NIH HHS N01 HC095167NHLBI NIH HHS N01 HC095168NHLBI NIH HHS N01 HC095169NHLBI NIH HHS R01 HL080477NHLBI NIH HHS R01 HL165452NHLBI NIH HHS U01 HL080295NHLBI NIH HHS U01 HL130114NIA NIH HHS R01 AG007181NIA NIH HHS R01 AG023629NIA NIH HHS R01 AG028507NIDDK NIH HHS K23 DK067303NIDDK NIH HHS P30 DK079626NIDDK NIH HHS R01 DK031801NIDDK NIH HHS R01 DK100446NIDDK NIH HHS R01 DK108803NINDS NIH HHS U01 NS041588NINDS NIH HHS UH3 NS100605
6 · The paper itself

Abstract

RATIONALE &

objectiveChronic kidney disease (CKD) is complicated by abnormalities that reflect disruption in filtration, tubular, and endocrine functions of the kidney. Our aim was to explore the relationship of specific laboratory result abnormalities and hypertension with the estimated glomerular filtration rate (eGFR) and albuminuria CKD staging framework. STUDY

designCross-sectional individual participant-level analyses in a global consortium. SETTING & STUDY POPULATIONS: 17 CKD and 38 general population and high-risk cohorts. SELECTION CRITERIA FOR STUDIES: Cohorts in the CKD Prognosis Consortium with data for eGFR and albuminuria, as well as a measurement of hemoglobin, bicarbonate, phosphorus, parathyroid hormone, potassium, or calcium, or hypertension. DATA EXTRACTION: Data were obtained and analyzed between July 2015 and January 2018. ANALYTICAL APPROACH: We modeled the association of eGFR and albuminuria with hemoglobin, bicarbonate, phosphorus, parathyroid hormone, potassium, and calcium values using linear regression and with hypertension and categorical definitions of each abnormality using logistic regression. Results were pooled using random-effects meta-analyses.

resultsThe CKD cohorts (n=254,666 participants) were 27% women and 10% black, with a mean age of 69 (SD, 12) years. The general population/high-risk cohorts (n=1,758,334) were 50% women and 2% black, with a mean age of 50 (16) years. There was a strong graded association between lower eGFR and all laboratory result abnormalities (ORs ranging from 3.27 [95% CI, 2.68-3.97] to 8.91 [95% CI, 7.22-10.99] comparing eGFRs of 15 to 29 with eGFRs of 45 to 59mL/min/1.73m LIMITATIONS: Variations in study era, health care delivery system, typical diet, and laboratory assays.

conclusionsLower eGFR was strongly associated with higher odds of multiple laboratory result abnormalities. Knowledge of risk associations might help guide management in the heterogeneous group of patients with CKD.

Indexed as

AgedAlbuminuriaBlood Chemical AnalysisCreatinineCross-Sectional StudiesDisease ProgressionFemaleGlobal HealthGlomerular Filtration RateHumansHypertension, RenalInternationalityKidney Function TestsMaleMiddle AgedPredictive Value of TestsCreatininealbuminuriaanemiaChronic kidney disease (CKD)CKD Prognosis ConsortiumCKD stagediabetesglomerular filtration rate (GFR)hematocrithemoglobinhyperparathyroidismhypertensionindividual-level meta-analysiskidney functionlaboratory abnormalitylaboratory testsmeta-analysisserum bicarbonateserum calciumserum intact parathyroid hormoneserum phosphorusserum potassiumstaging system

Identifiers

PMID30348535
PMCPMC6348050
OpenAlexW2896713857

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.